Results of the TCGA pan-cancer analysis revealed that a different expression level of CD101 could be observed in neoplastic sites compared to that of the normal tissues across majority of cancer types, with the exception of bladder urothelial carcinoma (BLCA), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), and kidney chromophobe (KICH) (Figure 1A). Here, CD101 is linked to diffuse large B-cell lymphoma.